A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease

• Published in: Evidence-based complementary and alternative medicine Vol. 2022; pp. 1 - 14
• Main Authors: Tan, Xi-Yue, Xie, Yu-Jia, Liu, Xing-Long, Li, Xin-Yun, Jia, Bo
• Format: Journal Article
• Language: English
• Published: New York Hindawi 26.06.2022; Hindawi Limited
• Subjects: Antibiotics; Clinical trials; Colonoscopy; Digestive system; Fecal microflora; Feces; Gastrointestinal tract; Infections; Inflammation; Inflammatory bowel disease; Inflammatory bowel diseases; Intestinal microflora; Intestine; Meta-analysis; Microbiota; Patients; Placebos; Remission; Remission (Medicine); Response rates; Safety; Software; Species richness; Systematic review; Transplantation; Transplants & implants; Australia
• ISSN: 1741-427X; 1741-4288
• DOI: 10.1155/2022/8266793

Objectives. Inflammatory bowel disease (IBD) is a chronic recurrent inflammatory disease of the gastrointestinal tract, and its prevalence is increasing worldwide. Fecal microbiota transplantation (FMT) is an emerging therapy that modifies the patient’s gut microbiota by transplanting feces from a healthy donor to achieve disease remission. However, its efficacy and safety need to be further investigated. Methods. PubMed, the Cochrane Library, Web of Science, Embase, and Google Scholar databases (up to 8th November 2021) were searched and literature was screened by title and abstract as well as full text. The primary outcome was clinical remission, with the clinical response as a secondary outcome. Risk ratios (RR) with 95% confidence intervals (CI) were reported. Results. A total of 14 trials were included in this study. In terms of clinical remission, FMT had a significant effect compared to placebo (RR = 1.44, 95 CI%: 1.03 to 2.02, I2 = 38%, P=0.03), with no significant risk of study heterogeneity. Moreover, FMT led to significant results in clinical response compared to placebo with moderate between-study heterogeneity (RR = 1.34, 95 CI%: 0.92 to 1.94, I2 = 51%, P=0.12). Subgroup analysis showed a higher clinical remission for fresh fecal FMT (40.9%) than that for frozen fecal FMT (32.2%); the efficacy of gastrointestinal (GI) pretreatment, the severity of disease, route of administration, and the donor selection remain unclear and require more extensive study. Safety analysis concluded that most adverse events were mild and self-resolving. The microbiological analysis found that the patient’s gut microbiota varied in favor of the donor, with increased flora diversity and species richness. Conclusion. FMT is a safe, effective, and well-tolerated therapy. Studies have found that fresh fecal microbiota transplant can increase clinical remission rates. However, more randomized controlled trials and long-term follow-ups are needed to assess its long-term effectiveness and safety.